FDA Greenlights Kythera’s Kybella
In a much anticipated approval, the FDA has given its nod to Kythera's Kybella to treat double chins.
In a much anticipated approval, the FDA has given its nod to Kythera's Kybella to treat double chins.
A new analysis points to aging patients, rising med-spa volume, and next-generation HA and biostimulatory formulas as drivers behind the projected jump to an $8.45B global fillers market.